Research Progress in Treatment of HR-Positive/HER 2-Low Advanced Breast Cancer: Interpretation of Breast Cancer Research Hotspots in 2024 ASCO

• Published in: Zhongliu fangzhi yanjiu Vol. 52; no. 2; pp. 98 - 102
• Main Authors: Ma, Yiwen, Xu, Junnan, Sun, Tao
• Format: Journal Article
• Language: Chinese; English
• Published: Tianjin China Anti-Cancer Association 01.02.2025; Magazine House of Cancer Research on Prevention and Treatment
• Subjects: Breast cancer; cdk4/6 inhibitors; Chemotherapy; ErbB-2 protein; her2-low expression; hr-positive; Lymph nodes; Metastases; Patients; t-dxd
• ISSN: 1000-8578
• DOI: 10.3971/j.issn.1000-8578.2025.24.1033

HR-positive HER2-low breast cancer is a new hotspot therapeutic subtype, accounting for approximately 53.7% of all breast cancers. Patients with this type of cancer tend to have a high rate of lymph node metastasis and poor sensitivity to neoadjuvant chemotherapy and conventional anti-HER2 therapy, and exploring therapeutic strategies for this subtype of patient is a current clinical challenge. Therapeutic strategies for HR-positive HER2-low breast cancer are constantly being updated, including CDK4/6 inhibitors across the lines of therapy, and next-generation antibody-drug conjugates such as T-DXd. With the accumulation of high-level evidence-based evidence for HR-positive HER2-low breast cancer in the future, the research data will provide more practical support for precise diagnosis and treatment, thereby improving the prognosis of patients with HR-positive HER2-low breast cancer.